Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lewerin, Catharina
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL	Recruiting	3	870	Europe	R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)	Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum	Mantle Cell Lymphoma	05/21	05/26
IbruOnOff, NCT04771507: A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)	Recruiting	1/2	50	Europe	Ibrutinib, Imbruvica	Jeanette Lundin	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	04/23	12/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lewerin, Catharina
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL	Recruiting	3	870	Europe	R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)	Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum	Mantle Cell Lymphoma	05/21	05/26
IbruOnOff, NCT04771507: A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)	Recruiting	1/2	50	Europe	Ibrutinib, Imbruvica	Jeanette Lundin	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	04/23	12/27